TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

RECRUITINGOBSERVATIONAL

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)

About This Trial

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of NVG - Patients who have received IVT-AFL treatment according to Japanese labeling. Who Should NOT Join This Trial: - Patients who are contraindicated based on approved label - Diagnosis of other indication Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Diagnosis of NVG * Patients who have received IVT-AFL treatment according to Japanese labeling. Exclusion Criteria: * Patients who are contraindicated based on approved label * Diagnosis of other indication

Treatments Being Tested

DRUG

Aflibercept (Eylea, BAY86-5321)

Administration by intravitreal injection

Locations (1)

Many locations

Multiple Locations, Japan